The legal fallout from the June 2026 short-seller report by Jehoshaphat Research continues to intensify as multiple law firms, including Hagens Berman and Robbins Geller, alert investors to an ongoing securities class action lawsuit against Gildan Activewear Inc. (NYSE: GIL). The litigation centers on allegations that the company engaged in 'channel stuffing'—the practice of inflating sales figures by shipping excess inventory to distributors beyond actual end-user demand. According to the allegations, this practice created a $500 million product overhang that was concealed from the market during the Class Period, which ran from February 19, 2025, to June 15, 2026. When the Jehoshaphat Research report, titled 'Stuffing All of the Channel Some of the Time?', was published on June 16, 2026, Gildan’s stock price plummeted 18.75%, or $11.62 per share, closing at $50.35. The complaint asserts that the company’s revenue growth was driven by unsustainable inventory pull-forwards rather than genuine market share gains, and that M&A disclosures regarding HanesBrands overstated synergies while masking distributor saturation. Investors have until December 14, 2026, to seek lead plaintiff status. From a forensic perspective, this case highlights the recurring risk of 'pull-forward' revenue recognition, where companies borrow from future quarters to meet current analyst expectations. The reliance on distributor saturation as a growth lever is a classic red flag that often precedes significant restatements or downward guidance revisions. ## Sources - PR Newswire — Hagens Berman alert regarding class action lawsuit, Oct 29, 2026. - Morningstar — Details on Jehoshaphat Research report and stock price impact, Oct 29, 2026. - PR Newswire — Deadline reminder for lead plaintiff status, Oct 29, 2026. - National Law Review — Summary of allegations regarding channel stuffing and revenue inflation.
Original reporting by PR Newswire. This article is desk analysis prepared by The Forensic Ledger from publicly available sources, summarized with citation to the original.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.
